RayKnowChina Research Map
Shortlist0

NanningGuangxi Medical University

Guangxi Medical University Cancer Hospital

广西医科大学附属肿瘤医院

Listed for 9 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Guangxi Medical University Cancer Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌48 papers led2 open trials led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌3 papers led
  3. Hepatocellular carcinoma肝细胞癌149 papers led2 open trials led
  4. Stomach cancer胃癌12 papers led
  5. Osteosarcoma骨肉瘤4 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  7. Ewing sarcoma尤文肉瘤1 paper led
  8. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎1 paper led
  9. Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led

Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, Neuroblastoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 48 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 2.0%.

Papers led
48
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
9
led by another institution
Papers led per year
2021: 8820212022: 121220222023: 9920232024: 8820242025: 11112025

5 hospitals in Nanning for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 11

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT05707819

    Age 18 years to 70 years (registered criteria)

    Led by Guangxi Medical University Cancer HospitalNanning

  2. Recruiting
    Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2020-06
    Registry
    NCT04376866

    Age 18 years to 65 years (registered criteria)

    Led by Guangxi Medical University Cancer HospitalNanning

  3. Recruiting
    PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07235319

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 4 listed hospitals as study sitesChangsha, Fuzhou, Guangzhou, Hangzhou, Nanning

  4. Recruiting
    Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07528183

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesFuzhou, Guangzhou, Nanning, Wuhan

  5. Recruiting
    QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06749899

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 17 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xiamen, Zhongshan

  6. Recruiting
    A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06839066

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Nanning, Shenzhen, Wuhan, Zhongshan

  7. Recruiting
    A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
    Phase
    Phase 1/Phase 2
    Started
    2025-11
    Registry
    NCT07258979

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Jiangmen, Kunming, Nanchang, Nanning, Shanghai, Shaoguan, Xiamen

  8. Recruiting
    Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07311772

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shanghai, Shantou, Wuzhou, Zhuhai

  9. Recruiting
    40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07328854

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shantou, Wuzhou, Zhongshan, Zhuhai

  10. Recruiting
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    Phase
    Phase 3
    Started
    2024-03
    Registry
    NCT06239727

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 21 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Nanchang, Nanjing, Nanning, Shantou, Tianjin, Wuhan, Xi'an, Xiamen, Zhanjiang

  11. Recruiting
    GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06455410

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 7 listed hospitals as study sitesFoshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AIInduction / concurrent chemotherapyRadiotherapy technique
Departments in papersRadiation oncologyRadiology / nuclear medicineMedical oncologyENT / head & neck surgery
Papers it led48
  1. Development and Validation of a Nomogram Based on the Different Grades of Cervical Lymph Node Necrosis to Predict Overall Survival in Patients with Lymph Node-Positive Locally Advanced Nasopharyngeal Carcinoma.2025Academic radiology
  2. Early circulating EBV-DNA clearance predicts enhanced short-term treatment response and survival benefit in locally advanced nasopharyngeal carcinoma.2025BMC cancerFree full text
  3. Integrated machine learning and single-cell analysis identify chromatin-remodeling gene signature for diagnosis and prognosis in nasopharyngeal carcinoma.2025Clinical and experimental medicineFree full text
  4. Genetic algorithm-optimized neural network outperforms TNM staging in predicting rapidly progressive nasopharyngeal carcinoma: Reassessing adjuvant chemotherapy benefit via propensity score matching.2025European journal of cancer (Oxford, England : 1990)
  5. An interpretable machine learning model assists in predicting induction chemotherapy response and survival for locoregionally advanced nasopharyngeal carcinoma using MRI: a multicenter study.2025European radiology
  6. Machine learning-derived prognostic signature for progression-free survival in non-metastatic nasopharyngeal carcinoma.2025Head & neck
  7. Efficacy and safety of Anlotinib in combination with gemcitabine and cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A single-arm clinical trial.2025International journal of cancer
  8. Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF.2025Oral oncology
  9. Prognostic nomogram for synchronous metastatic nasopharyngeal carcinoma: a retrospective multicentre study.2025Radiation oncology (London, England)Free full text
  10. Four-dimensional trapped ion mobility spectrometry proteomics reveals circulating extracellular vesicles encapsulated drivers of nasopharyngeal carcinoma distant dissemination.2025Talanta
  11. Risk factors and clinical prediction model for vertebral artery stenosis following radiotherapy for nasopharyngeal carcinoma.2025The Journal of international medical researchFree full text
  12. Efficacy of treatment patterns based on concurrent chemoradiotherapy in patients with stage IIB cervical squamous cell carcinoma.2024BMC cancerFree full text
  13. Nasopharyngeal cancer risk assessment by country or region worldwide from 1990 to 2019.2024BMC public healthFree full text
  14. Deep learning model using planar whole-body bone scintigraphy for diagnosis of skull base invasion in patients with nasopharyngeal carcinoma.2024Journal of cancer research and clinical oncologyFree full text
  15. Establishing subdivisions of M1 stage nasopharyngeal carcinoma based on decision tree classification: A multicenter retrospective study.2024Oral oncology
  16. A nomogram based on circulating CD8+ T cell and platelet-to-lymphocyte ratio to predict overall survival of patients with locally advanced nasopharyngeal carcinoma.2024Radiation oncology (London, England)Free full text
  17. Efficacy of metastatic lesion radiotherapy in patients with metastatic nasopharyngeal carcinoma: A multicenter retrospective study.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  18. Serum ferritin predicted prognosis in patients with nasopharyngeal carcinoma.2024Scientific reportsFree full text
  19. Short-term OS as a surrogate endpoint for 5-year OS in nasopharyngeal carcinoma in non-endemic area.2024World journal of surgical oncologyFree full text
  20. The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis.2023Cancer biology & therapyFree full text
  21. Regional lymph node density-based nomogram predicts prognosis in nasopharyngeal carcinoma patients without distant metastases.2023Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  22. Individualized number of induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma patients based on early tumor response.2023Cancer medicineFree full text
  23. STIM1-regulated exosomal EBV-LMP1 empowers endothelial cells with an aggressive phenotype by activating the Akt/ERK pathway in nasopharyngeal carcinoma.2023Cellular oncology (Dordrecht, Netherlands)Free full text
  24. Long-term outcomes of chemoradiotherapy versus radiotherapy alone in patients with intermediate-risk nasopharyngeal carcinoma: a population-based analysis.2023European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  25. A dynamic nomogram combining tumor stage and magnetic resonance imaging features to predict the response to induction chemotherapy in locally advanced nasopharyngeal carcinoma.2023European radiology
  26. The miRNA-185-5p/STIM1 Axis Regulates the Invasiveness of Nasopharyngeal Carcinoma Cell Lines by Modulating EGFR Activation-Stimulated Switch from E- to N-Cadherin.2023Molecules (Basel, Switzerland)Free full text
  27. Efficacy of induction chemotherapy in lymph node-positive stage III nasopharyngeal carcinoma and identification of beneficiaries based on clinical features: A propensity score matching analysis.2023Oral oncology
  28. Research trends of radiation induced temporal lobe injury in patients with nasopharyngeal carcinoma from 2000 to 2022: a bibliometric analysis.2023Radiation oncology (London, England)Free full text
  29. Sleep, depression, and anxiety in family caregivers of nasopharyngeal carcinoma patients before therapy.2022Acta psychologica
  30. MRI-based random survival Forest model improves prediction of progression-free survival to induction chemotherapy plus concurrent Chemoradiotherapy in Locoregionally Advanced nasopharyngeal carcinoma.2022BMC cancerFree full text
  31. Efficiency of high cumulative cisplatin dose in high- and low-risk patients with locoregionally advanced nasopharyngeal carcinoma.2022Cancer medicineFree full text
  32. A spectral CT-based nomogram for predicting the response to induction chemotherapy in nasopharyngeal carcinoma.2022Clinical radiology
  33. Nasopharyngeal Carcinoma Progression: Accumulating Genomic Instability and Persistent Epstein-Barr Virus Infection.2022Current oncology (Toronto, Ont.)Free full text
  34. A nomogram to predict survival and guide individualized induction chemotherapy in T3-4N1M0 nasopharyngeal carcinoma.2022Current problems in cancer
  35. Downregulation of annexin A3 promotes ionizing radiation-induced EGFR activation and nuclear translocation and confers radioresistance in nasopharyngeal carcinoma.2022Experimental cell research
  36. Development and validation of prognostic nomograms in patients with ascending type of nasopharyngeal carcinoma: Retrospective study based on SEER database.2022Head & neck
  37. Prognostic significance of wait time for radical radiotherapy in locoregionally advanced nasopharyngeal carcinoma.2022Head & neck
  38. A nomogram based on tumor response to induction chemotherapy may predict survival in locoregionally advanced nasopharyngeal carcinoma.2022Head & neck
  39. MRI-Based Back Propagation Neural Network Model as a Powerful Tool for Predicting the Response to Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma.2022Journal of magnetic resonance imaging : JMRI
  40. Survival among subgroups of patients with stage II nasopharyngeal carcinoma.2022Scientific reportsFree full text
  41. Is skeletal muscle loss associated with chemoradiotherapy toxicity in nasopharyngeal carcinoma patients? A prospective study.2021Clinical nutrition (Edinburgh, Scotland)
  42. Effect of chemotherapy on survival in patients with stage T3-4N0M0 nasopharyngeal carcinoma.2021Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
  43. PADI4, negatively regulated by miR-335-5p, participates in regulating the proliferation, migration, invasion and radiosensitivity of nasopharyngeal carcinoma cells.2021Journal of biological regulators and homeostatic agents
  44. Polyethylene glycol-coated ultrasmall superparamagnetic iron oxide nanoparticles-coupled sialyl Lewis X nanotheranostic platform for nasopharyngeal carcinoma imaging and photothermal therapy.2021Journal of nanobiotechnologyFree full text
  45. CD166 promotes cancer stem cell-like phenotype via the EGFR/ERK1/2 pathway in the nasopharyngeal carcinoma cell line CNE-2R.2021Life sciences
  46. Maximal lymph nodal diameter on N stage of nasopharyngeal carcinoma.2021MedicineFree full text
  47. Retropharyngeal lymph node metastasis on N stage of nasopharyngeal carcinoma.2021PloS oneFree full text
  48. Validation of Stage N3 of the Eighth Edition AJCC Staging System for Nasopharyngeal Carcinoma.2021The Laryngoscope
Chinese-language papers (not in the count)1
  1. [Progress of scRNA-seq technology in nasopharyngeal carcinoma research].2025Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgeryFree full text
All its trials on ClinicalTrials.gov, any status25
  1. Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal CarcinomaRecruitingNCT05707819Lead sponsorStart 2022-07
  2. Toripalimab for Local-regional Recurrent Nasopharyngeal CarcinomaRecruitingNCT04376866Lead sponsorPhase 3Start 2020-06
  3. Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II TrialStatus unknownNCT04992988Lead sponsorPhase 2Start 2020-06
  4. The Role of Adding Concurrent Chemotherapy to IMRT in the Treatment of Stage II Nasopharyngeal CarcinomaStatus unknownNCT02116231Lead sponsorPhase 2Start 2014-04
  5. Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal CarcinomaRecruitingNCT07528183Study sitePhase 2Start 2026-07
  6. PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPCRecruitingNCT07235319Study sitePhase 3Start 2026-04
  7. Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral LiquidRecruitingNCT07311772Study sitePhase 3Start 2025-12
  8. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Study sitePhase 3Start 2025-05
  9. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.RecruitingNCT07258979Study sitePhase 1/Phase 2Start 2025-11
  10. 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal CarcinomaRecruitingNCT07328854Study sitePhase 3Start 2025-11
  11. A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line TherapyRecruitingNCT06839066Study sitePhase 2Start 2025-04
  12. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponseRecruitingNCT06239727Study sitePhase 3Start 2024-03
  13. GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06455410Study sitePhase 2Start 2024-06
  14. Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT06712888Study sitePhase 3Start 2025-02
  15. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05126719Study sitePhase 2Start 2023-04
  16. Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)Active, not recruitingNCT05587374Study sitePhase 3Start 2023-08
  17. TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaCompletedNCT05563480Study sitePhase 2Start 2022-10
  18. PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal CarcinomaActive, not recruitingNCT04907370Study sitePhase 3Start 2021-08
  19. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08
  20. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)CompletedNCT03924986Study sitePhase 3Start 2019-03
  21. PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT03427827Study sitePhase 3Start 2018-07
  22. Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal CarcinomaStatus unknownNCT03700476Study sitePhase 3Start 2018-12
  23. Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02633176Study sitePhase 3Start 2015-01
  24. Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02944708Study sitePhase 3Start 2015-10
  25. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal CancerStatus unknownNCT01074021Study sitePhase 3Start 2009-10
More papers found outside PubMed (not counted)32
  1. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Researchconference-abstract
  2. An Integrated Analysis of RNA Sequencing and Molecular Docking Reveal EIF2AK2, IFIT1, and STAT1 as Key Targets of EGCG in Nasopharyngeal Carcinoma2025Research Squarepreprint
  3. Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: A randomized, controlled, multicenter, open-label study.2025Journal of Clinical Oncologyarticle
  4. Combination of Tim-3 blockade TQB2618 with penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, two-cohort, phase 2 study.2025Journal of Clinical Oncologyconference-abstract
  5. LBA35 Iza-Bren (BL-B01D1), an EGFR×HER3 bispecific antibody-drug conjugate, versus physician's choice of chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma: A randomized, open-label, multicenter, phase III, piv2025Annals of Oncologyconference-abstract
  6. Multi-Omics Mendelian Randomization Integrating GWAS, eQTL, RNA-seq and Cell Line Experiment Reveal GLIPR1 and ARHGAP11A as Potential Targets of EGCG for Nasopharyngeal Carcinoma2025Research Squarepreprint
  7. Optimization of the 9th Ajcc/Uicc Tnm Staging System for Nasopharyngeal Carcinoma Based on Age and Pretreatment Ebv DNA: Exploring Prognostic Stratification and Individualized Treatment Strategies for Stage Ii-Iii Patients2025SSRN Electronic Journalpreprint
  8. PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized2025Journal of Clinical Oncologyarticle
  9. Semen podocarpi extract enhances radiosensitivity in nasopharyngeal carcinoma cells via Raf/MEK/ERK signaling pathway2025Asian Pacific Journal of Tropical Biomedicinearticle
  10. Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal car2025Journal of Clinical Oncologyconference-abstract
  11. Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.2024Journal of Clinical Oncologyconference-abstract
  12. Analysis of proliferating Treg cells as a predictor for immunotherapy response using systemic longitudinal immune profiling: Biomarker analysis of the phase 3 CONTINUUM trial.2024Journal of Clinical Oncologyconference-abstract
  13. Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.2024Journal of Clinical Oncologyconference-abstract
  14. Long-term outcomes of anlotinib and penpulimab combined with chemotherapy in the treatment of patients with metastatic nasopharyngeal carcinoma that failed definitive platinum-based chemoradiotherapy.2024Journal of Clinical Oncologyconference-abstract
  15. PD-1 blockade with camrelizumab after chemoradiotherapy in nasopharyngeal carcinoma.2024Journal of Clinical Oncologyconference-abstract
  16. Prognostic Analysis of Nonmetastatic Nasopharyngeal Carcinoma in Older Patients Undergoing Intensity‐Modulated Radiotherapy2024International Journal of Clinical Practicearticle
  17. Safety and efficacy of iparomlimab and tuvonralimab in combination with gemcitabine and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase 2 trial (DUBHE-N-2024Journal of Clinical Oncologyconference-abstract
  18. 860MO MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic nasopharyngeal carcinoma2023Annals of Oncologyarticle
  19. PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM)2023Journal of Clinical Oncologyconference-abstract
  20. A phase Ib study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).2022Journal of Clinical Oncologyconference-abstract
  21. Analysis of hnRNP K Expression and Relevance for Clinical Outcomes in Hepatocellular carcinoma2022Research Squarepreprint
  22. Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.2022Journal of Clinical Oncologyconference-abstract
  23. Penpulimab plus gemcitabine in combination with cisplatin or anlotinib as first-line treatment for metastatic nasopharyngeal carcinoma (M NPC): A phase II study.2022Journal of Clinical Oncologyconference-abstract
  24. Upregulation of ITGAV and the underlying mechanisms in nasopharyngeal carcinoma2022Electronic Journal of Biotechnologyarticle
  25. ZBTB7A governs 2-DG-inhibited glycolysis by regulating GLUT1 in nasopharyngeal carcinoma2022Biocellarticle
  26. 436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy2021Journal for ImmunoTherapy of Cancerconference-abstract
  27. 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results2021Annals of Oncologyarticle
  28. A Nomogram to Predict Survival and Determine Necessity of Induction Chemotherapy for Patients With Stage T3-4N1 Nasopharyngeal Carcinoma2021Research Squarepreprint
  29. Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.2021Journal of Clinical Oncologyconference-abstract
  30. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncologyconference-abstract
  31. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.2021Journal of Clinical Oncologyconference-abstract
  32. Potential Role of The Upregulation of The Zinc Finger Protein of The Cerebellum 2 In Nasopharyngeal Carcinoma2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 3 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 002025

4 hospitals in Nanning for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07700667

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  2. Recruiting
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06644781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapyNeoadjuvant & combined treatmentSurgery
Departments in papersRadiation oncology
Papers it led3
  1. The predictors of lymphopenia and its effects on survival in locally advanced esophageal squamous cell carcinoma.2024Cancer biology & therapyFree full text
  2. Adjuvant treatment patterns for pT3N0M0 esophageal cancer undergoing surgery.2024Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  3. Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.2024Frontiers in immunologyFree full text
All its trials on ClinicalTrials.gov, any status7
  1. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  2. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  3. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11
  4. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Study sitePhase 2Start 2022-10
  5. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  6. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  7. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
More papers found outside PubMed (not counted)5
  1. 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  2. Research on the Expression and Mechanism of LRRC8D in Esophageal Squamous Cell Carcinoma2025Research Squarepreprint
  3. O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)2023Annals of Oncologyarticle
  4. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncologyconference-abstract
  5. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncologyarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 149 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 1.0%.

Papers led
149
2021–2025
Trials led
10
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 222220212022: 292920222023: 313120232024: 323220242025: 32322025

5 hospitals in Nanning for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 7

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Adjuvant TACE in HCC With High-risk Recurrence Factors
    Phase
    Phase 3
    Started
    2026-02
    Registry
    NCT07417397

    Age 18 years to 70 years (registered criteria)

    Led by Guangxi Medical University Cancer HospitalNanning

  2. Recruiting
    Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
    Phase
    Phase 2/Phase 3
    Started
    2021-06
    Registry
    NCT05062837

    Age 18 years to 75 years (registered criteria)

    Led by Guangxi Medical University Cancer HospitalNanning

  3. Recruiting
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Registry
    NCT07547553

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin

  4. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  5. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  6. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  7. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisSurgery & liver transplantImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineMedical oncologyRadiation oncology
Papers it led149
  1. Machine learning models for predicting microvascular invasion in hepatocellular carcinoma with three-dimensional whole-lesion 18F-FDG PET radiomics.2026Hellenic journal of nuclear medicine
  2. Tertiary lymphoid structures in HCC: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy.2026Hepatology (Baltimore, Md.)
  3. Genome-wide association study of HBV-related hepatocellular carcinoma identifies a functional variant at the FAM114A1 locus.2026Journal of genetics and genomics = Yi chuan xue bao
  4. Bimetallic Ca/Zn Nanoagonist Remould the Immunosuppressive Hepatocellular Carcinoma Microenvironment Following Incomplete Microwave Ablation via Pyroptosis and the STING Signaling Pathway.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  5. Immune infiltration landscape and potential drug-targeted implications for hepatocellular carcinoma with 'progression/hyper-progression' recurrence.2025Annals of medicineFree full text
  6. Preliminary experience of lenvatinib, tislelizumab and transcatheter arterial chemoembolization for BCLC stage C hepatocellular carcinoma: a phase II study.2025BMC cancerFree full text
  7. Platelet-albumin-bilirubin versus albumin-bilirubin as a predictor of long-term survival for hepatitis B-Induced hepatocellular carcinoma after hepatic resection.2025BMC cancerFree full text
  8. C-reactive protein to albumin ratio combined with the Systemic Inflammatory Response Index predicts the prognosis of patients undergoing radical hepatectomy.2025BMC cancerFree full text
  9. Multi-omics integration analysis of the amino-acid metabolism-related genes identifies putatively causal variants of ACCS associated with hepatitis B virus-related hepatocellular carcinoma survival.2025BMC cancerFree full text
  10. CK19 protein expression: the best cutoff value on the prognosis and the prognosis model of hepatocellular carcinoma.2025BMC cancerFree full text
  11. Tumor vascular occlusion by calcium-based thermosensitizer provokes continuous cavitation effect and thermal energy transition efficiency of radiofrequency ablation therapy.2025Biomaterials
  12. Comprehensive strategies for management of postoperative hyper-progression recurrence (HPR) of hepatocellular carcinoma: a 12-year large sample multi-center study.2025Cancer biology & medicineFree full text
  13. HBX Multi-Mutations Combined With Traditional Screening Indicators to Establish a Nomogram Contributes to Precisely Stratify the High-Risk Population of Hepatocellular Carcinoma.2025Cancer medicineFree full text
  14. CTSE inhibits anti-tumor T cell response by promoting des-γ-carboxy prothrombin releasing in hepatocellular carcinoma.2025Cell death & diseaseFree full text
  15. lncSNHG16 promotes hepatocellular carcinoma development by inhibiting autophagy.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  16. Novel genetic variants in the NLRP3 inflammasome-related PANX1 and APP genes predict survival of patients with hepatitis B virus-related hepatocellular carcinoma.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoFree full text
  17. Prognostic nomogram for hepatocellular carcinoma with major vascular invasion: a population-based study from the SEER database and a Chinese cohort.2025European journal of medical researchFree full text
  18. Up-regulated ITGB4 promotes hepatocellular carcinoma metastasis by activating hypoxia-mediated glycolysis and cancer-associated fibroblasts.2025European journal of pharmacology
  19. Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoin2025Frontiers in cellular and infection microbiologyFree full text
  20. Development of a machine learning model to predict overall survival for large hepatocellular carcinoma at BCLC stage A or B after curative hepatectomy.2025Frontiers in immunologyFree full text
  21. Predicting recurrence and recurrence-free survival in initially unresectable hepatocellular carcinoma: a novel nomogram for patients undergoing conversion hepatectomy with lenvatinib, PD-1 inhibitor, and interventional therapy.2025Frontiers in immunologyFree full text
  22. The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection.2025Frontiers in immunologyFree full text
  23. Application and prospect analysis of chimeric antigen receptor T-cell therapy in hepatocellular carcinoma treatment: a systematic review and meta-analysis.2025Frontiers in immunologyFree full text
  24. Clonorchis sinensis-infected hepatocellular carcinoma exhibits distinct tumor microenvironment and molecular features.2025Frontiers in immunologyFree full text
  25. Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit i2025Hepatology (Baltimore, Md.)
  26. MSNs-loaded HMME and Erastin-mediated ferroptosis combined with sonodynamic therapy for HCC treatment.2025Journal of cancer research and therapeutics
  27. Disruption of mitochondrial homeostasis by bimetallic ca/cu nanocomposites against hepatocellular carcinoma.2025Journal of controlled release : official journal of the Controlled Release Society
  28. Prognostic analysis and limited efficacy of adjuvant TACE in hepatocellular carcinoma following hepatectomy: a propensity score-matched study.2025Langenbeck's archives of surgeryFree full text
  29. Impact of Clonorchis sinensis infection on long-term survival after curative resection for hepatocellular carcinoma: A multicenter cohort study.2025PLoS neglected tropical diseasesFree full text
  30. Multi-omics analysis of lactate metabolism gene regulation in Clonorchis sinensis-associated hepatocellular carcinoma.2025Parasites & vectorsFree full text
  31. Clonorchis sinensis infection remodels chromatin accessibility in hepatocellular carcinoma.2025Parasites & vectorsFree full text
  32. The microRNA landscape and regulatory network in Clonorchis sinensis-infected hepatocellular carcinoma: implications for tumor progression.2025Parasites & vectorsFree full text
  33. Lysyl oxidase as a potential biomarker of lung recurrence after hepatectomy in hepatocellular carcinoma.2025Scientific reportsFree full text
  34. Sleep quality trajectories and their relationship with quality of life in patients with hepatocellular carcinoma: a prospective cohort study.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  35. Safety and efficacy of salvage surgery for unresectable hepatocellular carcinoma after conversion with triple therapy: a systematic review and meta-analysis of data from Chinese patients.2025World journal of surgical oncologyFree full text
  36. Silencing of KIF2C enhances the sensitivity of hepatocellular carcinoma cells to cisplatin through regulating the PI3K/AKT/MAPK signaling pathway.2024Anti-cancer drugs
  37. Genetic variants in m5C modification genes are associated with survival of patients with HBV-related hepatocellular carcinoma.2024Archives of toxicology
  38. Prognostic value of aspartate aminotransferase/alanine aminotransferase ratio in hepatocellular carcinoma after hepatectomy.2024BJS openFree full text
  39. Prognostic importance of the Scottish inflammatory prognostic score in patients with hepatocellular carcinoma after hepatectomy: a retrospective cohort study.2024BMC cancerFree full text
  40. Associations between modifiable risk factors and hepatocellular carcinoma: a trans-ancestry Mendelian randomization study.2024BMC cancerFree full text
  41. A novel surgical scheme for hepatectomy in hepatocellular carcinoma patients with clinically significant portal hypertension.2024BMC cancerFree full text
  42. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study.2024BMC cancerFree full text
  43. Nomogram for Predicting Postoperative Pulmonary Metastasis in Hepatocellular Carcinoma Based on Inflammatory Markers.2024Cancer control : journal of the Moffitt Cancer CenterFree full text
  44. Potentially functional genetic variants in ferroptosis-related CREB3 and GALNT14 genes predict survival of hepatitis B virus-related hepatocellular carcinoma.2024Cancer medicineFree full text
  45. Association between novel genetic variants of Notch signaling pathway genes and survival of hepatitis B virus-related hepatocellular carcinoma.2024Cancer medicineFree full text
  46. Functional genetic variants of the disulfidptosis-related INF2 gene predict survival of hepatitis B virus-related hepatocellular carcinoma.2024Carcinogenesis
  47. Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: A real-world observational study.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  48. Comprehensive analysis of the role of Netrin G1 (NTNG1) in hepatocellular carcinoma cells.2024European journal of pharmacology
  49. Integrative multi-omics analysis reveals a novel subtype of hepatocellular carcinoma with biological and clinical relevance.2024Frontiers in immunologyFree full text
  50. Dynamics trajectory of patient-reported quality of life and its associated risk factors among hepatocellular carcinoma patients receiving immune checkpoint inhibitors: a prospective cohort study.2024Frontiers in immunologyFree full text
  51. Developing an advanced diagnostic model for hepatocellular carcinoma through multi-omics integration leveraging diverse cell-death patterns.2024Frontiers in immunologyFree full text
  52. Integrating single-cell and bulk RNA sequencing reveals CK19 + cancer stem cells and their specific SPP1 + tumor-associated macrophage niche in HBV-related hepatocellular carcinoma.2024Hepatology international
  53. Combined Effects of Anti-PD-L1 and Nanosonodynamic Therapy on HCC Immune Activation in Mice: An Investigation.2024International journal of nanomedicineFree full text
  54. Development and validation of a nomogram for radiation-induced hepatic toxicity after intensity modulated radiotherapy for hepatocellular carcinoma: a retrospective study.2024Japanese journal of clinical oncologyFree full text
  55. Genetic variants of m6A modification genes are associated with survival of HBV-related hepatocellular carcinoma.2024Journal of cellular and molecular medicineFree full text
  56. Radiotherapy is superior to transarterial chemoembolization as adjuvant therapy after narrow-margin hepatectomy in patients with hepatocellular carcinoma: A single-center prospective randomized study.2024Langenbeck's archives of surgeryRCT
  57. Two case reports of breast cancer combined with synchronous primary intrahepatic cholangiocarcinoma/mixed liver cancer.2024MedicineFree full text
  58. Prevalence of Malnutrition in Patients with Hepatocellular Carcinoma: A Comparative Study of GLIM Criteria, NRS2002, and PG-SGA, and Identification of Independent Risk Factors.2024Nutrition and cancer
  59. Involvement of lncRNAs in the regulation of aerobic glycolysis in hepatocellular carcinoma: Main functions, regulatory mechanisms and potential therapeutic implications (Review).2024Oncology reportsFree full text
  60. Clonorchis sinensis infection contributes to hepatocellular carcinoma progression via enhancing angiogenesis.2024PLoS neglected tropical diseasesFree full text
  61. Clonorchis sinensis on the prognosis of patients with spontaneous rupture of Hepatocellular Carcinoma: An inverse probability of treatment weighting analysis.2024PLoS neglected tropical diseasesFree full text
  62. Clonorchis sinensis infection amplifies hepatocellular carcinoma stemness, predicting unfavorable prognosis.2024PLoS neglected tropical diseasesFree full text
  63. Associations of tumor-related psychiatric symptoms and healthy behaviors with dynamic quality of life after hepatocellular carcinoma hepatectomy.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerFree full text
  64. Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial.2024TrialsFree full text
  65. The dynamic variation position and predominant quasispecies of hepatitis B virus: Novel predictors of early hepatocarcinoma.2024Virus researchFree full text
  66. Adjuvant therapy for hepatocellular carcinoma: Dilemmas at the start of a new era.2024World journal of gastroenterologyFree full text
  67. Risk factors and nomogram predictive models for postsurgical progression/hyperprogression recurrence in hepatocellular carcinoma with macroscopic vascular invasion.2024World journal of surgical oncologyFree full text
  68. A Reliable and Repeatable Model for Predicting Microvascular Invasion in Patients With Hepatocellular Carcinoma.2023Academic radiology
  69. Serum immune biomarker levels combined with hepatitis B virus infection status predict early recurrence of early-stage hepatocellular carcinoma with microvascular invasion after liver resection.2023Acta chirurgica Belgica
  70. Letter: Entecavir versus tenofovir on serum lipoprotein levels of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy.2023Alimentary pharmacology & therapeutics
  71. Letter: repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma in ideal candidates.2023Alimentary pharmacology & therapeutics
  72. Specific gut microbiome signature predicts hepatitis B virus-related hepatocellular carcinoma patients with microvascular invasion.2023Annals of medicineFree full text
  73. Prognostic factors and an innovative nomogram model for patients with hepatocellular carcinoma treated with postoperative adjuvant transarterial chemoembolization.2023Annals of medicineFree full text
  74. Genetic variants of SOS2, MAP2K1 and RASGRF2 in the RAS pathway genes predict survival of HBV-related hepatocellular carcinoma patients.2023Archives of toxicology
  75. Liver resection for large and huge hepatocellular carcinoma: Predictors of failure, recurrence patterns, and prognoses.2023Asia-Pacific journal of clinical oncology
  76. Prognosis after hepatic resection of patients with hepatocellular carcinoma related to non-alcoholic fatty liver disease: meta-analysis.2023BJS openFree full text
  77. Prognostic potential of preoperative circulating tumor cells to predict the early progression recurrence in hepatocellular carcinoma patients after hepatectomy.2023BMC cancerFree full text
  78. The association of serum IL-33/ST2 expression with hepatocellular carcinoma.2023BMC cancerFree full text
  79. Mesenchymal circulating tumor cells and Ki67: their mutual correlation and prognostic implications in hepatocellular carcinoma.2023BMC cancerFree full text
  80. Hepatectomy combined with apatinib and camrelizumab for CNLC stage IIIb hepatocellular carcinoma: a phase II trial protocol.2023BMJ openFree full text
  81. Nomograms for postsurgical extrahepatic recurrence prediction of hepatocellular carcinoma based on presurgical circulating tumor cell status and clinicopathological factors.2023Cancer medicineRCTFree full text
  82. Association between telomere length and hepatocellular carcinoma risk: A Mendelian randomization study.2023Cancer medicineFree full text
  83. miR-17-5p slows progression of hepatocellular carcinoma by downregulating TGFβR2.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  84. Therapeutic Outcome of Stereotactic Body Radiotherapy for Small Hepatocellular Carcinoma Lesions - A Systematic Review and Network Meta-analysis.2023Clinical oncology (Royal College of Radiologists (Great Britain))
  85. Down-regulation of ALDOB during metabolic reprogramming mediates malignant behavior in hepatocellular carcinoma and insensitivity to postoperative adjuvant transarterial chemoembolization.2023Clinical science (London, England : 1979)
  86. Novel Long Noncoding RNAs, LINC01093 and MYLK-AS1, Serve as Potential Diagnostic and Prognostic Biomarkers or Hepatocellular Carcinoma.2023DNA and cell biology
  87. Is hepatectomy feasible for hepatocellular carcinoma patients with clinically significant portal hypertension and beyond the Milan criteria?2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  88. Comparison of survival rates as predicted by total tumor volume or tumor burden score in patients with hepatocellular carcinoma concurrent with fatty liver disease and hepatitis B virus.2023Expert review of gastroenterology & hepatology
  89. A functional variant in the RAD51 3' UTR is associated with survival of hepatocellular carcinoma patients.2023Gene
  90. A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma.2023International journal of molecular sciencesFree full text
  91. The Novel-Natural-Killer-Cell-Related Gene Signature Predicts the Prognosis and Immune Status of Patients with Hepatocellular Carcinoma.2023International journal of molecular sciencesFree full text
  92. Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study.2023Journal of gastroenterology
  93. Potentially functional genetic variants in RPS6KA4 and MAP2K5 in the MAPK signaling pathway predict HBV-related hepatocellular carcinoma survival.2023Molecular carcinogenesis
  94. Effects of Clonorchis sinensis combined with Hepatitis B virus infection on the prognosis of patients with Hepatocellular Carcinoma following Hepatectomy.2023PLoS neglected tropical diseasesFree full text
  95. Radiotherapy plus anti-PD1 versus radiotherapy for hepatic toxicity in patients with hepatocellular carcinoma.2023Radiation oncology (London, England)Free full text
  96. Establishment and validation of a prognostic pomogram in unresectable hepatocellular carcinoma treated with intensity modulated radiotherapy: a real world study.2023Radiation oncology (London, England)Free full text
  97. Non-classic radiation-induced liver disease after intensity-modulated radiotherapy for Child-Pugh grade B patients with locally advanced hepatocellular carcinoma.2023Radiation oncology (London, England)Free full text
  98. A three-gene signature reveals changes in the tumor immune microenvironment in the progression from NAFLD to HCC.2023Scientific reportsFree full text
  99. Efficacy comparison of optimal treatments for hepatocellular carcinoma patients with portal vein tumor thrombus.2022Annals of hepatologyRCT
  100. Repeat hepatic resection versus percutaneous ablation for the treatment of recurrent hepatocellular carcinoma: meta-analysis.2022BJS openFree full text
  101. Prognostic value of a nomogram based on peripheral blood immune parameters in unresectable hepatocellular carcinoma after intensity-modulated radiotherapy.2022BMC gastroenterologyRCTFree full text
  102. Preoperative fibrinogen-to-albumin ratio predicts the prognosis of patients with hepatocellular carcinoma subjected to hepatectomy.2022BMC gastroenterologyFree full text
  103. Combination of Preoperative Circulating Tumor Cell Count and Neutrophil-Lymphocyte Ratio for Prognostic Prediction in Hepatocellular Carcinoma Patients after Curative Hepatectomy.2022BioMed research internationalFree full text
  104. Fatty acid binding protein 5 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells by degradation of Krüppel-like factor 9 mediated by miR-889-5p via cAMP-response element binding protein.2022Cancer biology & therapyFree full text
  105. Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice.2022Cancer immunology, immunotherapy : CIIFree full text
  106. The positive feedback loop of furin and TGFβ1 enhances the immune responses of Tregs to hepatocellular carcinoma cells and hepatitis B virus in vitro.2022Cell biology international
  107. Inflammation and Fibrosis in Patients with Non-Cirrhotic Hepatitis B Virus-Associated Hepatocellular Carcinoma: Impact on Prognosis after Hepatectomy and Mechanisms Involved.2022Current oncology (Toronto, Ont.)Free full text
  108. A functional liver imaging score for preoperative prediction of liver failure after hepatocellular carcinoma resection.2022European radiology
  109. CCNB1 promotes the development of hepatocellular carcinoma by mediating DNA replication in the cell cycle.2022Experimental biology and medicine (Maywood, N.J.)Free full text
  110. Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future.2022Expert opinion on investigational drugs
  111. A novel risk score based on immune-related genes for hepatocellular carcinoma as a reliable prognostic biomarker and correlated with immune infiltration.2022Frontiers in immunologyFree full text
  112. Influence of clear cell carcinoma on the post-hepatectomy prognosis of patients with hepatocellular carcinoma.2022Future oncology (London, England)
  113. A new biomarker to enhance the radiosensitivity of hepatocellular cancer: miRNAs.2022Future oncology (London, England)
  114. Developmental artificial neural network model to evaluate the preoperative safe limit of future liver remnant volume for HCC combined with clinically significant portal hypertension.2022Future oncology (London, England)
  115. Outcomes of postoperative adjuvant transarterial chemoembolization for hepatocellular carcinoma according to the Ki67 index.2022Future oncology (London, England)
  116. Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial.2022Hepatology internationalFree full text
  117. Arecoline promotes proliferation and migration of human HepG2 cells through activation of the PI3K/AKT/mTOR pathway.2022HereditasFree full text
  118. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.2022Journal of gastroenterology and hepatology
  119. Clinical implications and biological features of a novel postoperative recurrent HCC classification: A multi-centre study.2022Liver international : official journal of the International Association for the Study of the Liver
  120. Effect of Body Composition on Outcomes in Patients with Hepatocellular Carcinoma Undergoing Radiotherapy: A Retrospective Study.2022Nutrition and cancer
  121. Integrative Analysis Reveals the Potential Role and Prognostic Value of GOLM1 in Hepatocellular Carcinoma.2022Oxidative medicine and cellular longevityFree full text
  122. Clonorchis sinensis infection contributes to hepatocellular carcinoma progression in rat.2022Parasitology research
  123. Prognostic value of long non-coding RNA MALAT1 in hepatocellular carcinoma: A study based on multi-omics analysis and RT-PCR validation.2022Pathology oncology research : PORFree full text
  124. Holliday Cross-Recognition Protein HJURP: Association With the Tumor Microenvironment in Hepatocellular Carcinoma and With Patient Prognosis.2022Pathology oncology research : PORFree full text
  125. Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study.2022Radiation oncology (London, England)Free full text
  126. Prognostic significance of combined α-fetoprotein and CA19-9 for hepatocellular carcinoma after hepatectomy.2022World journal of surgical oncologyFree full text
  127. Individual and joint influence of cytokeratin 19 and microvascular invasion on the prognosis of patients with hepatocellular carcinoma after hepatectomy.2022World journal of surgical oncologyFree full text
  128. Morphine may act via DDX49 to inhibit hepatocellular carcinoma cell growth.2021AgingFree full text
  129. Letter: elevated HBV DNA predicts poor survival in hepatocellular carcinoma after hepatic resection.2021Alimentary pharmacology & therapeutics
  130. Response to Comment on "'Development and Validation of a Nomogram to Preoperatively Estimate Post-hepatectomy Liver Dysfunction Risk and Long-term Survival in Patients With Hepatocellular Carcinoma': A 'Minimally-invasive' Step Forward".2021Annals of surgery
  131. Development and Validation of a Nomogram to Preoperatively Estimate Post-hepatectomy Liver Dysfunction Risk and Long-term Survival in Patients With Hepatocellular Carcinoma.2021Annals of surgery
  132. lncRNA Expression-Based Risk Scoring System Can Predict Survival of Tumor-Positive Patients with Hepatocellular Carcinoma.2021Asian Pacific journal of cancer prevention : APJCPFree full text
  133. Artificial neural network model to predict post-hepatectomy early recurrence of hepatocellular carcinoma without macroscopic vascular invasion.2021BMC cancerFree full text
  134. Safe standard remnant liver volume after hepatectomy in HCC patients in different stages of hepatic fibrosis.2021BMC surgeryFree full text
  135. Long Noncoding RNA FOXP4-AS1 Predicts Unfavourable Prognosis and Regulates Proliferation and Invasion in Hepatocellular Carcinoma.2021BioMed research internationalFree full text
  136. Development of a preoperative prognostic scoring system to predict benefits of hepatic resection in advanced hepatocellular carcinoma patients.2021Bioscience reportsFree full text
  137. Combination of serum paraoxonase/arylesterase 1 and antithrombin-III is a promising non-invasion biomarker for discrimination of AFP-negative HCC versus liver cirrhosis patients.2021Clinics and research in hepatology and gastroenterology
  138. Preoperative MR imaging for predicting early recurrence of solitary hepatocellular carcinoma without microvascular invasion.2021European journal of radiology
  139. Preoperative normalized iodine concentration derived from spectral CT is correlated with early recurrence of hepatocellular carcinoma after curative resection.2021European radiology
  140. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.2021Frontiers in immunologyFree full text
  141. Development and validation of prognostic nomograms in patients with hepatocellular carcinoma: a population-based study.2021Future oncology (London, England)
  142. Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.2021Hepatology international
  143. S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma.2021Hepatology international
  144. Combining Aspartate Aminotransferase-to-Platelet Ratio Index with Future Liver Remnant to Assess Preoperative Hepatic Functional Reserve in Patients with Hepatocellular Carcinoma.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  145. H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro.2021Medical science monitor : international medical journal of experimental and clinical researchFree full text
  146. Signature of prognostic epithelial-mesenchymal transition related long noncoding RNAs (ERLs) in hepatocellular carcinoma.2021MedicineFree full text
  147. C-terminal-truncated hepatitis B virus X protein promotes hepatocarcinogenesis by activating the MAPK pathway.2021Microbial pathogenesis
  148. Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study.2021Radiation oncology (London, England)Free full text
  149. Repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: retrospective multicentre study.2021The British journal of surgery
Chinese-language papers (not in the count)2
  1. [CCDC97 influences the immune microenvironment and biological functions in HCC].2025Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  2. Advances in post-operative prognostic models for hepatocellular carcinoma.2023Journal of Zhejiang University. Science. BFree full text
All its trials on ClinicalTrials.gov, any status24
  1. Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular CarcinomaStatus unknownNCT05131698Lead sponsorEarly phase 1Start 2021-03
  2. A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic ResectionStatus unknownNCT03914352Lead sponsorN/AStart 2019-04
  3. Adjuvant TACE in HCC With High-risk Recurrence FactorsRecruitingNCT07417397Lead (inferred)Phase 3Start 2026-02
  4. Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCCRecruitingNCT05062837Lead (inferred)Phase 2/Phase 3Start 2021-06
  5. A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of RecurrenceTerminatedNCT06851104Lead (inferred)Phase 2Start 2025-02
  6. HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCCCompletedNCT05532319Lead (inferred)Phase 2Start 2022-11
  7. DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular CarcinomaStatus unknownNCT04229355Lead (inferred)Phase 3Start 2021-02
  8. Association Between Autologous Transfusion and Recurrence-free Survival in Patients With HCC After ResectionCompletedNCT02654028Lead (inferred)N/AStart 2019-01
  9. Albumin for Hepatocellular CarcinomaStatus unknownNCT03974074Lead (inferred)Phase 3Start 2019-03
  10. Celebrex and Metformin for Postoperative Hepatocellular CarcinomaStatus unknownNCT03184493Lead (inferred)Phase 3Start 2017-06
  11. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCCRecruitingNCT07547553Study sitePhase 1/Phase 2Start 2026-05
  12. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  13. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  14. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  15. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  16. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Study sitePhase 3Start 2021-03
  17. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/BevActive, not recruitingNCT04649489Study sitePhase 3Start 2021-04
  18. A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationActive, not recruitingNCT04639180Study sitePhase 3Start 2021-04
  19. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Study sitePhase 3Start 2020-05
  20. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  21. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12
  22. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12
  23. Hepatocellular Carcinoma Registry in Asia: The INSIGHT RegistryCompletedNCT03233360Study siteStart 2017-04
  24. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma SubjectsStatus unknownNCT03236636Study sitePhase 3Start 2017-09

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 12 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
12
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 5520212022: 3320222023: 0020232024: 3320242025: 112025

2 hospitals in Nanning for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
    Phase
    Phase 2/Phase 3
    Started
    2026-03
    Registry
    NCT07221149

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Nanning, Shanghai

  2. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  3. Recruiting
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT06035250

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou

  4. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  5. Not yet recruiting
    Stomach-Partitioning Versus Conventional Gastrojejunostomy for Malignant Gastric Outlet Obstruction: A Multicenter Randomized Controlled Trial
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07561073

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanning

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AIPeritoneal spread & advanced diseaseChemotherapy & combined treatment
Departments in papersGastroenterology / hepatologyMedical oncologyNephrology
Papers it led12
  1. Stacking classifiers based on integrated machine learning model: fusion of CT radiomics and clinical biomarkers to predict lymph node metastasis in locally advanced gastric cancer patients after neoadjuvant chemotherapy.2025BMC cancerFree full text
  2. Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTI2024BMJ openFree full text
  3. Regulation of the PD-1/PD-L1 Axis and NK Cell Dysfunction by Exosomal miR-552-5p in Gastric Cancer.2024Digestive diseases and sciencesFree full text
  4. Random survival forest algorithm for risk stratification and survival prediction in gastric neuroendocrine neoplasms.2024Scientific reportsFree full text
  5. LTBP2 Knockdown Promotes Ferroptosis in Gastric Cancer Cells through p62-Keap1-Nrf2 Pathway.2022BioMed research internationalFree full text
  6. Effect of Esophagus-Remnant Stomach Anterior Wall Anastomosis on Postoperative Reflux and Nutritional Status in Patients with Early- and Intermediate-Stage Proximal Gastric Cancer.2022Journal of laparoendoscopic & advanced surgical techniques. Part A
  7. Nodal downstaging to ypN0 after neoadjuvant chemotherapy positively impacts on survival of cT4N+ GC/GEJ patients.2022Journal of surgical oncology
  8. Identified a disintegrin and metalloproteinase with thrombospondin motifs 6 serve as a novel gastric cancer prognostic biomarker by bioinformatics analysis.2021Bioscience reportsFree full text
  9. Diagnostic and prognostic value of plasma heat shock protein 90alpha in gastric cancer.2021International immunopharmacology
  10. Percentage of Natural Killer (NK) Cells in Peripheral Blood Is Associated with Prognosis in Patients with Gastric Cancer: A Retrospective Study from a Single Center.2021Medical science monitor : international medical journal of experimental and clinical researchFree full text
  11. Identification and verification of the molecular mechanisms and prognostic values of the cadherin gene family in gastric cancer.2021Scientific reportsFree full text
  12. A Novel Nomogram for Individually Predicting of Vascular Invasion in Gastric Cancer.2021Technology in cancer research & treatmentFree full text
All its trials on ClinicalTrials.gov, any status11
  1. Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric AdenocarcinomaStatus unknownNCT05122091Lead (inferred)Phase 2Start 2021-11
  2. Stomach-Partitioning Versus Conventional Gastrojejunostomy for Malignant Gastric Outlet Obstruction: A Multicenter Randomized Controlled TrialNot yet recruitingNCT07561073Study siteN/AStart 2026-10
  3. A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)RecruitingNCT07221149Study sitePhase 2/Phase 3Start 2026-03
  4. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  5. AI Prediction of Gastric Cancer Response to Neoadjuvant ChemotherapyRecruitingNCT06035250Study siteStart 2023-09
  6. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  7. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Study sitePhase 3Start 2024-05
  8. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  9. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  10. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  11. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 4 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 002025

12 hospitals in Nanning for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiation oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

3 hospitals in Nanning for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  2. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTCompletedNCT03465722Study sitePhase 3Start 2018-03

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

3 hospitals in Nanning for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 1 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Nanning for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. To analyze the efficacy and safety of plasma exchange in the treatment of anti-NMDA receptor encephalitis.2026Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Nanning for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

广西医科大学附属肿瘤医院

Guangxi Medical University Cancer Hospital

南宁

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Affiliated Tumor Hospital of Guangxi Medical University; Affiliated Cancer Hospital of Guangxi Medical University; Cancer Hospital of Guangxi Medical University; Affiliated Tumour Hospital of Guangxi Medical University; Guangxi Medical University Affiliated Tumor Hospital; Tumor Hospital of Guangxi Medical University; Guangxi Cancer Institute; Guangxi Cancer Molecular Medicine Engineering Research Center

Suggest a correctionDownload the data